Thermo Fisher to Invest More than $600 Million into Bioprocessing Production Expansions

Thermo Fisher Scientific announced on March 10, 2021 that it plans to invest more than $600 million into the expansion of its bioprocessing production capabilities through 2022.

According to a company press release, the investments are expected to double Thermo Fisher’s manufacturing capacity while creating more than 1500 jobs at 11 manufacturing sites in the Americas, Europe, and Asia. Specific expansions include:

• Single-use technologies—the company will expand its single-use technologies business at its sites in Logan, UT; Millersburg, PA; Cramlington, United Kingdom; Singapore; and Suzhou, China.
• Purification—Thermo Fisher plans to expand its POROS resin manufacturing site in Bedford, MA, and launch a new 85,000-ft2 manufacturing facility in Chelmsford, MA.
• Cell culture media and process liquid—expansions will take place at the company’s Grand Island, NY; Miami, FL; and Inchinnan, Scotland, sites to increase the production of cell culture media, supplements, and process liquids as well as the manufacturing of customer-owned proprietary media formulations.

"As the bioprocessing market grows, our customers require a consistent and reliable supply of critical materials. Single-use technologies, cell culture media, and purification resins are among those in highest demand," said Michel Lagarde, executive vice-president of Thermo Fisher Scientific, in the press release. "These investments add significant capacity and regional redundancy to further bolster supply chains and help us better support customers as they accelerate the commercialization of lifesaving therapies and vaccines."

Source: Thermo Fisher